Overview

A Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Cardiovascular Disease

Status:
Active, not recruiting
Trial end date:
2024-07-04
Target enrollment:
Participant gender:
Summary
This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a)
Phase:
Phase 3
Details
Lead Sponsor:
Chinese University of Hong Kong